The glycosylation landscape of pancreatic cancer (Review)

Munkley,Jennifer

doi:10.3892/ol.2019.9885

The glycosylation landscape of pancreatic cancer (Review)

Authors:
- Jennifer Munkley
View Affiliations

Affiliations: Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK
Published online on: January 3, 2019 https://doi.org/10.3892/ol.2019.9885
Pages: 2569-2575
Copyright: © Munkley . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic adenocarcinoma is a lethal disease with a 5‑year survival rate of <5%, the lowest of all types of cancer. The diagnosis of pancreatic cancer relies on imaging and tissue biopsy, and the only curative therapy is complete surgical resection. Pancreatic cancer has the propensity to metastasise at an early stage and the majority of patients are diagnosed when surgery is no longer an option. Hence, there is an urgent need to identify biomarkers to enable early diagnosis, and to develop new therapeutic strategies. One approach for this involves targeting cancer‑associated glycans. The most widely used serological marker in pancreatic cancer is the carbohydrate antigen CA 19‑9 which contains a glycan known as sialyl Lewis A (sLeA). The CA 19‑9 assay is used routinely to monitor response to treatment, but concerns have been raised about its sensitivity and specificity as a diagnostic biomarker. In addition to sLeA, a wide range of alterations to other important glycans have been observed in pancreatic cancer. These include increases in the sialyl Lewis X antigen (sLex), an increase in truncated O‑glycans (Tn and sTn), increased branched and fucosylated N‑glycans, upregulation of specific proteoglycans and galectins, and increased O‑GlcNAcylation. Growing evidence supports crucial roles for glycans in all stages of cancer progression, and it is well established that glycans regulate tumour proliferation, invasion and metastasis. The present review describes the biological significance of glycans in pancreatic cancer, and discusses the clinical value of exploiting aberrant glycosylation to improve the diagnosis and treatment of this deadly disease.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
3	Maitra A and Hruban RH: Pancreatic cancer. Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar : PubMed/NCBI
4	Klöppel G and Adsay NV: Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med. 133:382–387. 2009.PubMed/NCBI
5	Meezan E, Wu HC, Black PH and Robbins PW: Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry. 8:2518–2524. 1969. View Article : Google Scholar : PubMed/NCBI
6	Munkley J and Elliott DJ: Hallmarks of glycosylation in cancer. Oncotarget. 7:35478–35489. 2016. View Article : Google Scholar : PubMed/NCBI
7	Feizi T: Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 314:53–57. 1985. View Article : Google Scholar : PubMed/NCBI
8	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kailemia MJ, Park D and Lebrilla CB: Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem. 409:395–410. 2017. View Article : Google Scholar : PubMed/NCBI
10	Munkley J: Glycosylation is a global target for androgen control in prostate cancer cells. Endocr Relat Cancer. 24:R49–R64. 2017. View Article : Google Scholar : PubMed/NCBI
11	Mereiter S, Balmaña M, Gomes J, Magalhães A and Reis CA: Glycomic approaches for the discovery of targets in gastrointestinal cancer. Front Oncol. 6:552016. View Article : Google Scholar : PubMed/NCBI
12	Adamczyk B, Tharmalingam T and Rudd PM: Glycans as cancer biomarkers. Biochim Biophys Acta. 1820:1347–1353. 2012. View Article : Google Scholar : PubMed/NCBI
13	Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, et al: Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine. 8:103–116. 2016. View Article : Google Scholar : PubMed/NCBI
14	Munkley J, Mills IG and Elliott DJ: The role of glycans in the development and progression of prostate cancer. Nat Rev Urol. 13:324–333. 2016. View Article : Google Scholar : PubMed/NCBI
15	Moniaux N, Andrianifahanana M, Brand RE and Batra SK: Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br J Cancer. 91:1633–1638. 2004. View Article : Google Scholar : PubMed/NCBI
16	Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H and Ginsburg V: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 257:14365–14369. 1982.PubMed/NCBI
17	Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M, Mitchell KF, Steplewski Z and Koprowski H: A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science. 212:55–56. 1981. View Article : Google Scholar : PubMed/NCBI
18	Herlyn M, Sears HF, Steplewski Z and Koprowski H: Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 2:135–140. 1982. View Article : Google Scholar : PubMed/NCBI
19	Magnani JL, Steplewski Z, Koprowski H and Ginsburg V: Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 43:5489–5492. 1983.PubMed/NCBI
20	Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, Kaul K, Moser AJ, Zeh H, Brand RE and Haab BB: Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics. 11:3665–3674. 2011. View Article : Google Scholar : PubMed/NCBI
21	Lahdenne P, Pitkänen S, Rajantie J, Kuusela P, Siimes MA, Lanning M and Heikinheimo M: Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: Developmental changes and use in pediatric germ cell tumors. Pediatr Res. 38:797–801. 1995. View Article : Google Scholar : PubMed/NCBI
22	Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kalthoff H, Kreiker C, Schmiegel WH, Greten H and Thiele HG: Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 46:3605–3607. 1986.PubMed/NCBI
24	Tang H, Hsueh P, Kletter D, Bern M and Haab B: The detection and discovery of glycan motifs in biological samples using lectins and antibodies: New methods and opportunities. Adv Cancer Res. 126:167–202. 2015. View Article : Google Scholar : PubMed/NCBI
25	Shah UA and Saif MW: Tumor markers in pancreatic cancer: 2013. JOP. 14:318–321. 2013.PubMed/NCBI
26	Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, Kendrick ML and Farnell MB: Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 13:2050–2058. 2009. View Article : Google Scholar : PubMed/NCBI
27	Galli C, Basso D and Plebani M: CA 19-9: Handle with care. Clin Chem Lab Med. 51:1369–1383. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, Brenner DE, Kaul K, Zeh H, Moser AJ, et al: Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 6:e291802011. View Article : Google Scholar : PubMed/NCBI
29	Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z and Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 47:5501–5503. 1987.PubMed/NCBI
30	Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F and Hollingsworth MA: Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 19:1981–1993. 2013. View Article : Google Scholar : PubMed/NCBI
31	Partyka K, Maupin KA, Brand RE and Haab BB: Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics. 12:2212–2220. 2012. View Article : Google Scholar : PubMed/NCBI
32	Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, Huang Y, Brand RE and Haab BB: Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell Mol Gastroenterol Hepatol. 2:201–221.e215. 2016. View Article : Google Scholar : PubMed/NCBI
33	Xu HL, Zhao X, Zhang KM, Tang W and Kokudo N: Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer. World J Gastroenterol. 20:12171–12181. 2014. View Article : Google Scholar : PubMed/NCBI
34	Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA and Steplewski Z: Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 48:5422–5426. 1988.PubMed/NCBI
35	Singh S, Pal K, Yadav J, Tang H, Partyka K, Kletter D, Hsueh P, Ensink E, Kc B, Hostetter G, et al: Upregulation of glycans containing 3′ fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins. J Proteome Res. 14:2594–2605. 2015. View Article : Google Scholar : PubMed/NCBI
36	Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, et al: Glycan motif profiling reveals plasma sialyl-lewis × elevations in pancreatic cancers that are negative for sialyl-lewis A. Mol Cell Proteomics. 14:1323–1333. 2015. View Article : Google Scholar : PubMed/NCBI
37	Balmaña M, Sarrats A, Llop E, Barrabés S, Saldova R, Ferri MJ, Figueras J, Fort E, de Llorens R, Rudd PM and Peracaula R: Identification of potential pancreatic cancer serum markers: Increased sialyl-Lewis X on ceruloplasmin. Clin Chim Acta. 442:56–62. 2015. View Article : Google Scholar : PubMed/NCBI
38	Natoni A, Macauley MS and O'Dwyer ME: Targeting selectins and their ligands in cancer. Front Oncol. 6:932016. View Article : Google Scholar : PubMed/NCBI
39	Takahashi S, Oda T, Hasebe T, Sasaki S, Kinoshita T, Konishi M, Ueda T, Nakahashi C, Ochiai T and Ochiai A: Overexpression of sialyl Lewis × antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology. 69:127–135. 2001. View Article : Google Scholar : PubMed/NCBI
40	Rho JH, Mead JR, Wright WS, Brenner DE, Stave JW, Gildersleeve JC and Lampe PD: Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics. 96:291–299. 2014. View Article : Google Scholar : PubMed/NCBI
41	Metzgar RS, Gaillard MT, Levine SJ, Tuck FL, Bossen EH and Borowitz MJ: Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 42:601–608. 1982.PubMed/NCBI
42	Kawa S, Tokoo M, Oguchi H, Furuta S, Homma T, Hasegawa Y, Ogata H and Sakata K: Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 9:692–697. 1994. View Article : Google Scholar : PubMed/NCBI
43	Munkley J: The role of Sialyl-Tn in cancer. Int J Mol Sci. 17:2752016. View Article : Google Scholar : PubMed/NCBI
44	Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, Vakhrushev SY, Olsen JV, Hansen L, Bennett EP, et al: Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci USA. 111:E4066–E4075. 2014. View Article : Google Scholar : PubMed/NCBI
45	Hofmann BT, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, Picksak AS, Harder S, El Gammal AT, Grupp K, et al: COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 14:1092015. View Article : Google Scholar : PubMed/NCBI
46	Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US and Kim YS: Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology. 100:1691–1700. 1991. View Article : Google Scholar : PubMed/NCBI
47	Chugh S, Meza J, Sheinin YM, Ponnusamy MP and Batra SK: Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: Augmented aggressiveness and aberrant ErbB family glycosylation. Br J Cancer. 114:1376–1386. 2016. View Article : Google Scholar : PubMed/NCBI
48	Wang Y, Ju T, Ding X, Xia B, Wang W, Xia L, He M and Cummings RD: Cosmc is an essential chaperone for correct protein O-glycosylation. Proc Natl Acad Sci USA. 107:9228–9233. 2010. View Article : Google Scholar : PubMed/NCBI
49	Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T and Hollingsworth MA: Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 30:4843–4854. 2011. View Article : Google Scholar : PubMed/NCBI
50	Pan S, Tamura Y, Chen R, May D, McIntosh MW and Brentnall TA: Large-scale quantitative glycoproteomics analysis of site-specific glycosylation occupancy. Mol Biosyst. 8:2850–2856. 2012. View Article : Google Scholar : PubMed/NCBI
51	Pan S, Chen R, Tamura Y, Crispin DA, Lai LA, May DH, McIntosh MW, Goodlett DR and Brentnall TA: Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J Proteome Res. 13:1293–1306. 2014. View Article : Google Scholar : PubMed/NCBI
52	Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A and Lawrence TS: Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68:3803–3809. 2008. View Article : Google Scholar : PubMed/NCBI
53	Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolós C, Figueras J, de Llorens R, et al: α2,3-Sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol. 45:1748–1757. 2013. View Article : Google Scholar : PubMed/NCBI
54	Pérez-Garay M, Arteta B, Pagès L, de Llorens R, de Bolòs C, Vidal-Vanaclocha F and Peracaula R: alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One. 5(pii): e125242010. View Article : Google Scholar : PubMed/NCBI
55	Hsieh CC, Shyr YM, Liao WY, Chen TH, Wang SE, Lu PC, Lin PY, Chen YB, Mao WY, Han HY, et al: Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis. Oncotarget. 8:7691–7709. 2017. View Article : Google Scholar : PubMed/NCBI
56	Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE and Haab BB: The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics. 8:1697–1707. 2009. View Article : Google Scholar : PubMed/NCBI
57	Park HM, Hwang MP, Kim YW, Kim KJ, Jin JM, Kim YH, Yang YH, Lee KH and Kim YG: Mass spectrometry-based N-linked glycomic profiling as a means for tracking pancreatic cancer metastasis. Carbohydr Res. 413:5–11. 2015. View Article : Google Scholar : PubMed/NCBI
58	Zhao J, Qiu W, Simeone DM and Lubman DM: N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res. 6:1126–1138. 2007. View Article : Google Scholar : PubMed/NCBI
59	Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, Kamihagi K, Koyama N, Yamada S, Daigo Y, et al: Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta. 417:48–53. 2013. View Article : Google Scholar : PubMed/NCBI
60	Barrabés S, Pagès-Pons L, Radcliffe CM, Tabarés G, Fort E, Royle L, Harvey DJ, Moenner M, Dwek RA, Rudd PM, et al: Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology. 17:388–400. 2007. View Article : Google Scholar : PubMed/NCBI
61	Fardini Y, Dehennaut V, Lefebvre T and Issad T: O-GlcNAcylation: A new cancer hallmark? Front Endocrinol (Lausanne). 4(99)2013.PubMed/NCBI
62	Bond MR and Hanover JA: A little sugar goes a long way: The cell biology of O-GlcNAc. J Cell Biol. 208:869–880. 2015. View Article : Google Scholar : PubMed/NCBI
63	Liu Y, Cao Y, Pan X, Shi M, Wu Q, Huang T, Jiang H, Li W and Zhang J: O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. Cell Death Dis. 9:4852018. View Article : Google Scholar : PubMed/NCBI
64	Qian K, Wang S, Fu M, Zhou J, Singh JP, Li MD, Yang Y, Zhang K, Wu J, Nie Y, et al: Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer. J Biol Chem. 293:13989–14000. 2018. View Article : Google Scholar : PubMed/NCBI
65	Konrad RJ and Kudlow JE: The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med. 10:535–539. 2002.PubMed/NCBI
66	Ma Z, Vocadlo DJ and Vosseller K: Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem. 288:15121–15130. 2013. View Article : Google Scholar : PubMed/NCBI
67	Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD and Hart GW: Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem. 279:30133–30142. 2004. View Article : Google Scholar : PubMed/NCBI
68	Banerjee S, Sangwan V, McGinn O, Chugh R, Dudeja V, Vickers SM and Saluja AK: Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J Biol Chem. 288:33927–33938. 2013. View Article : Google Scholar : PubMed/NCBI
69	Garg B, Giri B, Majumder K, Dudeja V, Banerjee S and Saluja A: Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. Cancer Lett. 388:64–72. 2017. View Article : Google Scholar : PubMed/NCBI
70	Sharma NS, Gupta VK, Dauer P, Kesh K, Hadad R, Giri B, Chandra A, Dudeja V, Slawson C, Banerjee S, et al: O-GlcNAc modification of oncogenic transcription factor Sox2 promotes protein stability and regulates self-renewal in pancreatic cancer. bioRxiv. doi: https://doi.org/10.1101/345223.
71	Dwek RA, Butters TD, Platt FM and Zitzmann N: Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov. 1:65–75. 2002. View Article : Google Scholar : PubMed/NCBI
72	Vasconcelos-Dos-Santos A, Oliveira IA, Lucena MC, Mantuano NR, Whelan SA, Dias WB and Todeschini AR: Biosynthetic machinery involved in aberrant glycosylation: Promising targets for developing of drugs against cancer. Front Oncol. 5:1382015. View Article : Google Scholar : PubMed/NCBI
73	Iozzo RV and Sanderson RD: Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 15:1013–1031. 2011. View Article : Google Scholar : PubMed/NCBI
74	Pan S, Chen R, Stevens T, Bronner MP, May D, Tamura Y, McIntosh MW and Brentnall TA: Proteomics portrait of archival lesions of chronic pancreatitis. PLoS One. 6:e275742011. View Article : Google Scholar : PubMed/NCBI
75	Pan S, Chen R, Reimel BA, Crispin DA, Mirzaei H, Cooke K, Coleman JF, Lane Z, Bronner MP, Goodlett DR, et al: Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis. 30:1132–1144. 2009. View Article : Google Scholar : PubMed/NCBI
76	Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, et al: Pancreatic cancer proteome: The proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology. 129:1187–1197. 2005. View Article : Google Scholar : PubMed/NCBI
77	Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H and Ungefroren H: Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem. 277:36118–36128. 2002. View Article : Google Scholar : PubMed/NCBI
78	Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Büchler MW and Friess H: Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun. 322:943–949. 2004. View Article : Google Scholar : PubMed/NCBI
79	Koninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Büchler MW and Friess H: Overexpressed decorin in pancreatic cancer: Potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res. 10:4776–4783. 2004. View Article : Google Scholar : PubMed/NCBI
80	Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G and Gress TM: Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 121:657–667. 2001. View Article : Google Scholar : PubMed/NCBI
81	Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H and Büchler MW: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 88:12–20. 2000. View Article : Google Scholar : PubMed/NCBI
82	Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander AD and Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 102:1662–1673. 1998. View Article : Google Scholar : PubMed/NCBI
83	Whipple CA, Young AL and Korc M: A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene. 31:2535–2544. 2012. View Article : Google Scholar : PubMed/NCBI
84	Aikawa T, Whipple CA, Lopez ME, Gunn J, Young A, Lander AD and Korc M: Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest. 118:89–99. 2008. View Article : Google Scholar : PubMed/NCBI
85	Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 523:177–182. 2015. View Article : Google Scholar : PubMed/NCBI
86	Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E, Figueroa JA, et al: Galectins in cancer: Carcinogenesis, diagnosis and therapy. Ann Transl Med. 2:882014.PubMed/NCBI
87	Qian D, Lu Z, Xu Q, Wu P, Tian L, Zhao L, Cai B, Yin J, Wu Y, Staveley-O'Carroll KF, et al: Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Cancer Lett. 397:43–51. 2017. View Article : Google Scholar : PubMed/NCBI
88	Zhao W, Ajani JA, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z and Song S: Galectin-3 mediates tumor cell-stroma interactions by activating pancreatic stellate cells to produce cytokines via integrin signaling. Gastroenterology. 154:1524–1537.e6. 2018. View Article : Google Scholar : PubMed/NCBI
89	Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A and Brentnall TA: Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther. 13:899–907. 2012. View Article : Google Scholar : PubMed/NCBI
90	Chen R, Dawson DW, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, May DH, Crispin DA, Lai LA, Lay AR, et al: Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Lab Invest. 95:43–55. 2015. View Article : Google Scholar : PubMed/NCBI
91	Martinez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, Munné-Collado J, Iglesias M, André S, Gabius HJ, Hwang RF, Poirier F, et al: Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 74:3512–3524. 2014. View Article : Google Scholar : PubMed/NCBI
92	Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, et al: Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci USA. 115:E3769–E3778. 2018. View Article : Google Scholar : PubMed/NCBI
93	Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM and Cheresh DA: Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discov. 7:1464–1479. 2017. View Article : Google Scholar : PubMed/NCBI
94	Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al: Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 531:47–52. 2016. View Article : Google Scholar : PubMed/NCBI